Key result
Carotid plaque echolucency, measured by lower integrated backscatter values, predicted future coronary events in patients with chronic CAD achieving LDL-C goals on statin therapy.
Why the study?
Does ultrasound assessment of carotid plaque echolucency predict coronary events in chronic CAD patients who achieve LDL-C goals on statin therapy?
Cohort (n=357)
Blinded endpoint adjudication
Yes
Does ultrasound assessment of carotid plaque echolucency predict coronary events in chronic CAD patients who achieve LDL-C goals on statin therapy?
Carotid plaque echolucency assessed by integrated backscatter is a useful predictor of residual coronary risk in patients with chronic CAD who have achieved LDL-C goals on statin therapy.
Answers are grounded in this paper and cite their sources.
May aid residual risk stratification via carotid ultrasound in statin-treated CAD; hypothesis-generating and should not yet change practice.
BACKGROUND: Ultrasound assessment of either intima-media thickness (IMT) or plaque echolucency of the carotid artery provides prognostic information on coronary events. This study examined the hypothesis that IMT and plaque echolucency of the carotid artery may remain useful for prediction of coronary events in patients with coronary artery disease (CAD) after achievement of LDL-C goals on statin therapy. METHODS AND RESULTS: Ultrasound assessment of carotid maximum IMT (maxIMT) and plaque echolucency with integrated backscatter (IBS) analysis was performed in 357 chronic CAD patients with LDL-C <100mg/dl on statin therapy. All patients were prospectively followed up until the occurrence of one of the following coronary events: cardiac death, non-fatal myocardial infarction, or unstable angina pectoris requiring unplanned revascularization. During a mean follow-up of 32±18 months, 33 coronary events occurred. On multivariate Cox proportional hazards analysis, plaque echolucency (lower IBS value) was a significant predictor of coronary events (HR, 0.44; 95% CI: 0.29-0.73; P=0.009), whereas maxIMT was not. The addition of plaque echolucency to traditional risk factors improved net reclassification improvement (NRI) and integrated discrimination improvement (IDI; NRI, 0.59; P=0.0013; and IDI, 0.075; P=0.0009). CONCLUSIONS: Measurement of echolucency of the carotid artery was useful for assessment of residual coronary risk in CAD patients after LDL-C goal attainment on statin treatment.
No takes yet. Share an insight, caveat, or question.
Uematsu et al. (2013) conducted a cohort in Chronic coronary artery disease (n=357). Carotid plaque echolucency (lower integrated backscatter value) vs. Higher integrated backscatter value (less echolucent plaque) was evaluated on Coronary events (cardiac death, non-fatal myocardial infarction, or unstable angina pectoris requiring unplanned revascularization) (HR 0.44, 95% CI 0.29-0.73, p=0.009). Carotid plaque echolucency, measured by lower integrated backscatter values, predicted future coronary events in patients with chronic CAD achieving LDL-C goals on statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: